
# Title 21 - Food and Drugs
## Chapter I - Food and Drug Administration, Department of Health and Human Services
### Subchapter C - Drugs: General
#### PART 201 - LABELING
##### Subpart C - Labeling Requirements for Over-the-Counter Drugs
###### ยง 201.80 Specific requirements on content and format of labeling for human prescription drug and biological products; older drugs not described in ยง 201.56(b)(1).
####### a,name of drug,second, third, or all,s,name of drug,kinds of animal,s,x,name of drug

() If adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of a risk in later trimesters), the labeling shall state: "Studies in pregnant women have not shown that () increases the risk of fetal abnormalities if administered during the first () trimester() of pregnancy. If this drug is used during pregnancy, the possibility of fetal harm appears remote. Because studies cannot rule out the possibility of harm, however, () should be used during pregnancy only if clearly needed." The labeling shall also contain a description of the human studies. If animal reproduction studies are available and they fail to demonstrate a risk to the fetus, the labeling shall also state: "Reproduction studies have been performed in (()) at doses up to () times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to ()." The labeling shall also contain a description of available data on the effect of the drug on the later growth, development, and functional maturation of the child.
